Alkem Laboratories is coming out with a 100% book building; initial public offering (IPO) of 12,853,442 shares of Rs 2 each in a price band Rs 1020-1050 per equity share to raise upto Rs 1,350 crore. Not more than 50% of the issue will be allocated to Qualified Institutional Buyers (QIBs), including 5% to the mutual funds. Further, not less than 15% of the issue will be available for the non-institutional bidders and the remaining 35% for the retail investors.
The issue will open for subscription on December 8, 2015 and will close on December 10, 2015. The shares will be listed on BSE as well as NSE. The face value of the share is Rs 2 and is priced 510 times of its face value on the lower side and 525 times on the higher side.
Book running lead managers to the issue are Nomura Financial Advisory and Securities (India), Axis Capital, J.P. Morgan India and Edelweiss Financial Services, while compliance officer for the issue is Manish Narang.
Incorporated in 1973, Alkem Labs is leading India based pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. Alkem Labs produces branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals, which they market in India and 55 countries internationally, primarily the United States.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |